Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

Korábbi kezelés

• Patients who have had a definite diagnosis of Hp infection and have been treated with antibiotic eradication therapy.
• Continuous use of anti-ulcer drugs, antibiotics or bismuth complexes (taken at least 2 weeks prior to the screening for Hp infection)
• Having undergone upper gastrointestinal surgery.
• Received other clinical trials within the past 3 months

Más betegség

• Patients with contraindications to or allergies to the study drug.
• Patients with severe organ damage and complications (e.g., cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine disease
• Evidence of bleeding or iron deficiency anemia.
• History of malignancy.
• History of drug or alcohol abuse within the last 1 year.
• Those with psychiatric disorders.

Laborértékek

• Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except for the use of aspirin ≤100 mg/d)

Egyéb

• Pregnant and lactating women.
• Have symptoms of dysphagia.
• Refusal to sign the informed consent form.

• Age 18 to 70 years, regardless of gender.
• Patients with definite Hp infection (positive for either 13C/14C urea breath test, rapid urease test, and fecal Hp antigen test) and who have not received H. pylori eradication therapy.
• Voluntary Hp eradication therapy.
• Women of childbearing potential are required to use a medically advisable form of contraception during the trial and for 30 days after the trial ends.